Suzhou Zelgen Biosciences completed a $62M series B financing to support its portfolio of small molecule and biologic drug candidates.
January 15, 2018 -- Suzhou Zelgen Biosciences completed a $62 million series B financing to support its portfolio of small molecule and biologic drug candidates. Established in 2009, Zelgen is focused on cancer, hematology and auto-immune products. With the new capital, the company will advance its portfolio and prepare for commercialization of its lead product, a Phase III candidate that targets various forms of late-stage solid tumor cancers. The company also offers biologic CRO services.
